Introduction {#s1}
============

Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease worldwide.[@b1],[@b2] The spectrum of NAFLD ranges from simple steatosis and non-alcoholic steatohepatitis (NASH) to cirrhosis. Obesity is considered a key player in the development of NAFLD, and the majority of patients with NAFLD are either obese or overweight. However, NAFLD has been reported in lean subjects residing in developing countries as well as developed countries.[@b3]--[@b9] Lean NAFLD may represent a distinct entity, rather than merely a by-product of different body mass index (BMI). Moreover, NAFLD in the lean subjects suggests a phenotypic distinctiveness that raises the possibility of a different pathophysiology.

There is no standard definition of lean NAFLD, and BMI cut-off points for overweight and obesity are not uniform across the world. Studies have shown that for a given BMI, Asians generally have a higher proportion of body fat than do Europeans.[@b10] Asian populations have also been shown to have an elevated risk of type 2 diabetes mellitus (DM), hyperlipidaemia and hypertension at a relatively low level of BMI. Therefore, the recommended BMI cut-off points for Asians for defining overweight (23--25 kg/m^2^) and obesity (\>25 kg/m^2^) are lesser than those of Western populations.[@b10] The term "lean NAFLD" is used to describe fatty liver in patients who are not overweight or obese, as per region-specific BMI. Therefore, NAFLD with BMI \<23 kg/m^2^ for Asian populations and \<25 kg/m^2^ for non-Asian populations are considered lean NAFLD. The respective BMI cut-off points for non-obese NAFLD are \<25 kg/m^2^ and 30 kg/m^2^, respectively.

Epidemiology {#s2}
============

The study population and diagnostic modalities used in the diagnosis of NAFLD impact the assessment of NAFLD epidemiology.[@b1] Several diagnostic modalities have been used for the diagnosis of fatty liver, including ultrasound, liver enzymes, computed tomography, magnetic resonance imaging spectroscopy (MRS) and liver biopsy. Among these, ultrasound is perhaps the most practical way to assess hepatic steatosis, due to its relatively low cost, fair accuracy and non-invasive nature. Liver enzymes may be within normal range in a significant proportion of NAFLD patients; therefore, those levels cannot be used to exclude the presence of NAFLD reliably.

Liver biopsy is the gold standard; however, it is not feasible or ethical to perform liver biopsies in all suspected cases. MRS is highly accurate for even minimal amounts of steatosis; however, its cost limits its use in routine clinical practice. Most population studies have used ultrasound scan for the diagnosis of fatty liver ([Table 1](#t01){ref-type="table"}). Even ultrasound, though, is far from being accurate; it is operator-dependent, and has limited sensitivity and specificity for the diagnosis of fatty liver. A meta-analysis of 46 studies[@b11] revealed that application of ultrasound for the evaluation of hepatic steatosis had sensitivity of 73.3% and specificity of 69.6%, when compared to histopathology as the reference standard.

###### Prevalence of NAFLD among lean and non-obese subjects

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study^Ref^                  Country         *n*                                          Mode of diagnosis                               Prevalence         
  --------------------------- --------------- -------------------------------------------- ----------------------------------------------- ------------------ -------------
  Younossi *et al.*[@b12]     United States   11,613                                       USG                                             9.6%               28.8%

  Xu *et al.*[@b16]           China           6,905[\*](#table1fn1){ref-type="table-fn"}   USG                                             7.2%               Not studied

  Das *et al.*[@b3]           India           1,911                                        USG/CT[\*\*](#table1fn2){ref-type="table-fn"}   5.1%               31.7%

  Kwon *et al.*[@b14]         Korea           29,994                                       USG                                             12.6%              50.1%

  Bellentani *et al.*[@b13]   Italy           257                                          USG                                             16.4%              75.8%

  Sinn *et al.*[@b15]         Korea           5,878[\*](#table1fn1){ref-type="table-fn"}   USG                                             27% (non-obese)\   Not studied
                                                                                                                                           16% (lean)         

  Wei *et al.*[@b18]          Hong Kong       911                                          MRS                                             19.3%              60.5%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Only non-obese population.

CT scan was used during second phase to confirm NAFLD.

Abbreviations: CT, computed tomography; MRS, magnetic resonance spectroscopy; USG, ultrasonography.

The reported prevalence rates of NAFLD among lean and non-obese subjects in the literature are summarized in [Table 1](#t01){ref-type="table"}. In a recent study from the Unites States, population prevalence of NAFLD was estimated using data from the National Health and Nutrition Examination Survey III (NHANES III) database.[@b12] Among the 11,613 eligible participants, 18.8% had NAFLD and 3.7% had lean NAFLD. The overall prevalence of NAFLD among lean subjects was 9.67% (431/4457), whereas it was 28.8% (2061/7156) in the non-lean subjects.[@b12] This was the largest study published so far on the prevalence of lean NAFLD using a nationwide sample. Also, the lean NAFLD patients were less likely to have components of metabolic syndrome (MS).

In a prospective community-based epidemiological study from rural India, overall prevalence of NAFLD was 8.7% (164/1911),[@b3] while the prevalence among lean individuals (BMI \<23 kg/m^2^) was 5.1%. Among NAFLD subjects, 75% had a BMI lower than 25 kg/m^2^ and 54% were not even overweight. However, extrapolating this data to other populations would be difficult because the entire screened population had unusually low BMI. Overall, 87% of the participants were lean and only 7% had BMI \>25 kg/m^2^.

Data from the Dionysos study in northern Italy, which utilized ultrasonography to determine steatosis in 257 subjects, showed that the prevalence of NAFLD in the lean, non-drinking population was 16.4%, while in the obese population the prevalence was 75.8%.[@b13] In a study from Korea (*n* = 29994), the prevalence of NAFLD was 12.6% in non-obese (BMI \<25 kg/m^2^) subjects and 50.1% in obese subjects.[@b14] This is the largest community-based study from the East. In another Korean study, where data of 5,878 non-obese (BMI \<25 kg/m^2^), non-diabetic individuals were analysed, the prevalence of NAFLD was 27%. When only lean subjects were considered (BMI \<23 kg/m^2^), the prevalence of NAFLD was still considerably high, at 16%.[@b15] In a study from China, the prevalence of NAFLD was 7.27% in 6,905 non-obese subjects; among these, 5,562 subjects who were free of NAFLD at baseline completed the 5-year follow-up study, with 494 (8.8%) having developed NAFLD.[@b16] In that study, an increase in BMI and waist circumference (WC) was found to be independently associated with development of NAFLD during follow-up.

It is difficult to establish the prevalence of NASH in the general population because of the need of liver histology. Non-invasive methods cannot accurately determine the histological severity and prognosis of liver damage. Most studies have diagnosed NASH on the basis of criteria such as elevated liver enzymes, presence of DM or insulin resistance (IR). In the NHANES III study,[@b12] NAFLD patients with elevated liver enzymes in presence of DM or IR were presumed to have NASH, and the prevalence of presumed NASH in non-obese subjects was 0.1%. In an autopsy series of 351 apparently non-alcoholic patients, Wanless *et al.*[@b17] found that 18.5% of markedly obese subjects and 2.7% of lean subjects had steatohepatitis.

A major limitation of most of the ultrasound-based studies remains the poor accuracy of the ultrasound when hepatic steatosis is \<30%, for which ultrasound tends to underestimate the true prevalence of NAFLD. Mild steatosis may constitute an important proportion among the patients with lean NAFLD. That is why a higher (19.3%) prevalence rate of NAFLD was found in a study from HongKong when MRS was used as diagnostic modality.[@b18] Thus, it is increasingly clear that NAFLD is not so rare in lean subjects. The variations in the prevalence rates suggest that further studies, using consistent and accurate diagnostic modalities, are needed to provide true prevalence of lean NAFLD worldwide. Also, attempts should be made to provide estimates of the global prevalence of lean NASH using liver histology.

Clinical and metabolic characteristics {#s3}
======================================

Lean NAFLD patients are often asymptomatic; and, compared to obese NAFLD patients, they have lower body weight and WC. This is why many of such patients fail to seek medical advice. However, compared to lean healthy controls, lean NAFLD patients have higher BMI, blood pressure, fasting blood sugar, and higher prevalence of dyslipidaemia and MS.[@b5] The demographic and metabolic characteristics of lean and non-obese NAFLD patients have been summarised in [Table 2](#t02){ref-type="table"}.

###### Demographic and metabolic profiles of lean NAFLD patients in different studies

  Study,^Ref^ Country                *n*   Age[^\*^](#table2fn1){ref-type="table-fn"} (years)   Male: Female   BMI[^\*^](#table2fn1){ref-type="table-fn"} (kg/m^2^)   WC[^\*^](#table2fn1){ref-type="table-fn"} (cm)   DM (%)   HOMA-IR[^\*^](#table2fn1){ref-type="table-fn"}   HTN (%)   AST/ALT[^\*^](#table2fn1){ref-type="table-fn"} (IU/L)   Serum Chol/TG/HDL[^\*^](#table2fn1){ref-type="table-fn"} (mg/dL)
  ---------------------------------- ----- ---------------------------------------------------- -------------- ------------------------------------------------------ ------------------------------------------------ -------- ------------------------------------------------ --------- ------------------------------------------------------- ------------------------------------------------------------------
  Younossi *et al.*,[@b12] USA       431   42                                                   187:244        22.1                                                   NA                                               6.7      2.7                                              17.8      21/17                                                   NA
  Honda *et al.*,[@b8] Japan         134   56                                                   57:77          22.8                                                   NA                                               32       3.4                                              NA        47/70                                                   213/144/57
  Feng *et al.*,[@b9] China          134   48                                                   72:62          22.7                                                   82                                               15       2.1                                              34        21/21                                                   5.2/1.7/1.4[^\#^](#table2fn2){ref-type="table-fn"}
  Alam *et al.*,[@b6] Bangladesh     119   41                                                   62:57          23.0                                                   87                                               26       1.9                                              21        43/52                                                   202/243/36
  Kumar *et al.*,[@b5] India         27    38                                                   19:08          21.7                                                   80                                               3.7      1.7                                              15        38/45                                                   203/190/40
  Leung *et al.*,[@b4] Hong Kong     29    56                                                   13:16          22.1                                                   79                                               52       NA                                               41        25/45                                                   3.7/1.4/1.5[^\#^](#table2fn2){ref-type="table-fn"}
  Kim *et al.*,[@b7] Korea           74    51                                                   48:26          23.4                                                   83                                               10       2.6                                              43        23/31                                                   208/194/44
  Bhat *et al.*,[@b85] India         30    39                                                   NA             21.7                                                   84                                               NA       3.5                                              NA        NA/69                                                   177/185/38
  Akyuz *et al.*,[@b79] Turkey       37    41                                                   26:11          23.6                                                   NA                                               27       2.8                                              NA        49/82                                                   211/167/47
  Margariti *et al.*,[@b86] Greece   19    19                                                   11:08          \<25                                                   94                                               5        NA                                               16        45/92                                                   223/145/51

Data expressed in mean or median. NA: Data not available.

Data in mmol/L.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Chol, total cholesterol; DM, diabetes mellitus; HDL, high density lipoprotein; HOMA-IR, homeostasis model assessment insulin resistance; HTN, hypertension; TG, triglyceride; WC, waist circumference.

The metabolic characteristics of lean NAFLD subjects vary across ethnicities. A study revealed that lean, non-alcoholic, non-diabetic, non-smoking Asian Indians--in comparison to age-, sex- and BMI-matched Caucasians, Hispanics, Blacks and Eastern Asians--had a 2- to 3-fold increase in IR and 2-fold increase in hepatic steatosis.[@b19] Vos *et al.*[@b20] reported that compared with obese NAFLD patients, lean NAFLD patients were younger, mostly male, and displayed lower fasting glucose, glycated haemoglobin and blood pressure values. Using data from NHANES III, Younossi *et al.*[@b12] found that lean NAFLD was associated with younger age, female sex, and a decreased chance of having IR and hypercholesterolemia. A slight male preponderance has been found in the majority of studies on lean NAFLD, with the age ranging between 19 years and 56 years ([Table 2](#t02){ref-type="table"}).

Visceral obesity {#s4}
================

NAFLD in lean individuals may be linked to the compartmentalization of fat at ectopic sites, such as waist and neck. Visceral obesity may play an important role in the pathogenesis of lean NAFLD. It is believed that not all excessive body fat is harmful, rather visceral obesity seems to be the metabolically hazardous one, being the main source of fatty acids and mediators of steatosis, inflammation and fibrosis.[@b21],[@b22] One explanation for the existence of hepatic steatosis in lean subjects could be the concept of metabolically obese, normal weight subjects.[@b23] These normal BMI subjects develop hepatic steatosis after becoming a little heavier during adult life, with a 2 to 10 kg increase in weight, which was almost entirely due to an increase in body fat.[@b23],[@b24]

WC and neck circumference are commonly used as surrogate markers of visceral adiposity. Ha *et al.*[@b25] found that visceral adiposity rendered non-obese healthy Asian subjects more susceptible to NAFLD, as compared with subcutaneous fat and BMI. Li *et al.*[@b26] reported that neck circumference was an independent indicator for NAFLD in non-obese men. Considering that the body structure and fat deposition are different between males and females, we need to have anthropometric data categorized between male and female cases of lean NAFLD.

It should be noted that the WC has poor correlation with visceral obesity, as it also includes subcutaneous fat of the abdominal wall.[@b27],[@b28] In fact, subcutaneous fat may act a reservoir for excess lipids and might protect subjects against NAFLD by storing away extra fats.[@b27] The recently-introduced sagittal abdominal diameter measurement, which is taken as the antero-posterior diameter of the abdomen, may have a stronger correlation with visceral adiposity, particularly among non-obese (BMI \<25 kg/m^2^) subjects.[@b29]

Environmental factors {#s5}
=====================

There seems to be an association between dietary habit and development of lean NAFLD. There are several well-known animal models and genetic diseases that can lead to hepatic steatosis without significant adiposity or IR. A concept related to that is the methionine and choline-deficient diet mouse model.[@b30] Mice subjected to methionine and choline-deficient diet do not become IR or obese, but develop hepatic steatosis as a consequence of decreased beta-oxidation of fatty acids, a decrease in very low density lipoproteins (VLDLs), and a reduction in triglyceride export from hepatocytes.[@b31]

Fructose ingestion may play an important role in development of NAFLD in lean subjects. A study found soft drink consumption to be significantly associated with hepatic steatosis, independent of metabolic risk factors.[@b32] Non-obese NAFLD subjects have been found to consume higher amounts of added sugar, such as soft drinks and juices, compared to healthy controls.[@b33] Furthermore, consumption of high cholesterol diet may lead to NAFLD in lean subjects, even when the total caloric intake may not be excessive.

A study found that cholesterol intake was significantly higher in non-obese NAFLD patients than their obese NAFLD counterparts.[@b34] In an Italian study, consumption of higher cholesterol was noted in NASH patients with normal BMI compared to the BMI-matched controls.[@b35] The metabolites of cholesterol, such as oxysterols, serve as endogenous ligands for the liver X receptor a (LXRa), which also mediates sterol regulatory element binding protein 1c (SREBP1c) activation, ultimately increasing *de novo* lipogenesis and hepatic steatosis.[@b36] Increased expression of LXRa has been found in patients with non-obese NAFLD, as compared with obese ones.[@b37],[@b38] Cholesterol may promote apoptosis of hepatocytes and macrophages, formation of reactive oxygen species, and lipid peroxidation.[@b39],[@b40]

Genetic predisposition {#s6}
======================

Several genetic variants have been associated with NAFLD, with or without IR or other metabolic risk factors. Considering inter-ethnic variations in susceptibility, genetic factors may be important in the lean subjects with NAFLD.

Palatin-like phospholipase domain-containing 3 (PNPLA3) {#s6-1}
-------------------------------------------------------

PNPLA3 is a widely studied gene encoding for adiponutrin. The Dallas Heart Study found a strong association between hepatic steatosis and a variant allele (rs738409) of PNPLA3.[@b41] Asian populations were also shown to have a higher prevalence of the PNPLA3 148M polymorphism associated with steatosis, as compared with that observed in Europeans and Africans.[@b42] A population-based study from Hong Kong revealed that a higher proportion of patients with non-obese NAFLD than those with obese NAFLD carried the variant PNPLA3 allele (78.4% vs. 59.8%), and the PNPLA3 polymorphism remained an independent risk factor for non-obese NAFLD after adjusting for other metabolic risk factors.[@b18]

PNPLA3 rs738409 may affect the pathogenesis of NAFLD in non-obese individuals compared with obese individuals, and may have an additive joint effect along with such changes in lifestyle as weight gain \>10 kg after age 20.[@b43] Notably, the PNPLA3 variant is associated not only with hepatic steatosis but also with more aggressive forms of NAFLD, such as NASH, fibrosis and liver cancer.[@b44],[@b45] The mechanism by which the PNPLA3 polymorphism may cause NAFLD remains poorly understood. However, data suggest that it is not mediated through IR, obesity or dyslipidemia.[@b46],[@b47] Some plausible mechanisms could be impairment of hepatocellular lipolysis, remodelling of lipid droplets, and interference with VLDL secretion and retinol metabolism via retinyl-palmitate lipase activity.[@b48]--[@b50]

Cholesteryl ester transfer protein (CETP) {#s6-2}
-----------------------------------------

CETP plays an important role in transport of cholesterol from peripheral tissue back to the liver. Two single nucleotide polymorphisms (SNPs) on the CETP gene, namely rs12447924 and rs12597002, have been found to be associated with an increased risk of hepatic steatosis, particularly in non-obese subjects.[@b51]

Sterol regulatory element binding protein (SREBP) {#s6-3}
-------------------------------------------------

The SREBP gene codes the SREBP-2 transcription factor that regulates genes involved in the biosynthesis, uptake and excretion of cholesterol.[@b52] A recent study found that SREBP-2 polymorphism (rs133291) was associated with development of NAFLD in non-obese subjects without other metabolic risk factors.[@b53] Furthermore, SREBP-2 was associated with severity of NAFLD and with higher odds of NASH (odds ratio: 2.9) among patients with non-obese NAFLD.[@b53]

Apolipoprotein 3 (APOC3) {#s6-4}
------------------------

Lean Indian men with NAFLD were found to carry two gain-of-function SNPs within the gene encoding APOC3.[@b54] The variant allele carriers had a 30% increase in plasma APOC3 and a 60% increase in plasma triglycerides, as well as marked IR.

IR {#s7}
==

IR is an important trigger for initiation of NAFLD. NAFLD has been shown to be associated with IR independently of BMI,[@b55] and studies have reported that IR is present in a significant proportion of lean NAFLD patients even without other metabolic risk factors.[@b7],[@b56] A study revealed that lean, non-alcoholic Asian Indians had 2- to 3-fold increase in IR in comparison to matched Caucasians, Hispanics, Blacks and Eastern Asians.[@b19] However, IR is not universally present in all lean NAFLD patients. Several studies have revealed that lean NAFLD patients have little or no IR.[@b5],[@b12]

Various genetic factors are known to confer susceptibility to NAFLD in individuals without IR.[@b46],[@b47],[@b57] Patients with mutations in adipose triglyceride lipase and comparative gene identification-58 have been found to have severe steatosis but no IR.[@b58] A genetic variant in PNPLA3 has been shown to be associated with hepatic steatosis without IR.[@b57] A recent study on the effect of vitamin E in patients with NAFLD has found a significant improvement in hepatic histology without any change in IR.[@b59]

The discrepancies in the reports of presence or absence of IR in lean NAFLD can be partly explained by the facts that IR measured by the homeostasis model assessment-insulin resistance (HOMA-IR) index reflects only hepatic IR, while peripheral IR may be still present in such patients. IR at adipose tissue may trigger excess release of fatty acids, leading to development of hepatic lipotoxicity in NAFLD. However, convincing data to suggest that peripheral IR plays an important role in the pathogenesis of lean NAFLD is lacking. A study has reported that patients with NASH have severe adipose tissue IR independent of the degree of obesity.[@b60] In a recent study, Feldman *et al.*[@b61] have found that lean subjects with NAFLD are insulin resistant and have evidence of dysfunctional adipose tissues. Additional works are needed to gain a better understanding of this association.

Dyslipidaemia {#s8}
=============

Several studies have revealed a frequent occurrence of dyslipidaemia in lean NAFLD patients.[@b5],[@b6],[@b12],[@b62] The liver plays an important role in lipid metabolism and may be involved in the development of dyslipidaemia in NAFLD.[@b62] Impaired hepatic lipid handling may occur in patients with NAFLD, causing faulty lipid homeostasis and initiation of dyslipidaemia. Individuals with dyslipidaemia without obesity are termed as normal weight dyslipidaemia. The estimates of prevalence of normal weight dyslipidaemia in the general population range from 10% to 37%.[@b63]

Several new studies suggest an important role of intrahepatic fat in the development of dyslipidaemia and IR in humans.[@b64],[@b65] In cases with IR, hepatic fat deposition is further propagated, as the resulting hyperinsulinemia and hyperglycaemia activate SREBP and carbohydrate-SREBP, respectively. These transcription factors up-regulate *de novo* lipogenesis and, subsequently, hepatic lipid accumulation.[@b66] Furthermore, cholesterol metabolites such as oxysterols mediate SREBP1c activation, ultimately enhancing lipogenesis and hepatic steatosis.[@b36]

A study by Kim *et al.*[@b67] demonstrated that triglyceride levels were significantly associated with both the development and regression of NAFLD among non-obese Koreans. Oxidized low-density lipoprotein (LDL) is a powerful immunogenic molecule, which causes oxidative stress and produces antibodies (i.e. oxLDL-ab). A study has revealed that oxLDL-ab/HDL ratio is associated with severity of hepatocellular ballooning and liver fibrosis in lean NAFLD patients. This ratio could play an important role in distinguishing mild from severe states of NAFLD.[@b68]

Cytokines and adipokines {#s9}
========================

Cytokines play important roles in the pathogenesis of NAFLD. The macrophages residing in the adipose tissue remain important source of cytokines.[@b69],[@b70] Cytokine profile alteration in NAFLD patients has been associated with degree of adiposity. However, it appears that alterations in the levels of cytokines (TNF α, IL-1 and IL-6) and adipokines (leptin and adiponectin) are not significantly different between lean and obese NAFLD subjects.[@b5],[@b71]

The adipose tissues of lean NAFLD patients may have more pro-inflammatory potential. In fact, cytokine secretion has been related to adipocyte location and size. Visceral adipocytes tend to be smaller than subcutaneous adipocytes but, nonetheless, have greater potential to secrete cytokines.[@b21],[@b72] The visceral adiposities have been documented in lean NAFLD patients. Another trigger for cytokine production in NAFLD could be small intestinal bacterial overgrowth (SIBO) and the resulting endotoxemia.[@b73] In several studies, SIBO and endotoxin from gut-derived bacteria have been shown as associated with NAFLD.[@b73]--[@b75] However, similar data pertaining to lean NAFLD is not yet available.

Secondary causes of hepatic steatosis {#s10}
=====================================

NAFLD is commonly associated with DM, obesity, dyslipidaemia and IR; however, other less common specific conditions can cause hepatic steatosis. These are hypobetalipoproteinaemia, celiac disease, cystic fibrosis, lipodystrophy, hepatitis C virus infection, severe surgical weight loss, Wilson's disease, total parental nutrition and inflammatory bowel disease.[@b76]--[@b78] Several drugs, such as amiodarone, tamoxifen, methotrexate and corticosteroids, have been implicated in the causation of fatty liver.[@b78] While evaluating a lean patient with NAFLD, these causes must be taken into account, as they may require a different approach in the diagnosis and treatment.

Pathological characteristics {#s11}
============================

The underlying pathophysiologic basis of NAFLD in lean subjects remains uncertain, with conflicting data. It appears that there is no single pathway to this multifactorial phenotype. Genetic predisposition acting together with environmental influences, such as dietary composition and gut microbiome may have an important role. Polymorphisms in genes affecting lipid metabolism, oxidative stress, IR and immune regulation have been identified as predisposing factors for the development of NAFLD. The peripheral IR might contribute to steatosis by increasing lipolysis and delivery of free fatty acids to the liver. It is likely that multiple hits, acting together on genetically predisposed lean subjects induce NAFLD.

The published series that have included liver biopsy of non-obese NAFLD cases have yielded conflicting and inconclusive results. In general, patients with lean NAFLD tend to have less severe disease compared to obese patients ([Table 3](#t03){ref-type="table"}). Kumar *et al.*[@b5] reported that the mean NAFLD activity score in lean NAFLD patients was significantly lower than that in obese NAFLD patients (3.3 ± 1.5 vs. 4.1 ± 1.4, *p* \< 0.001). However, 28% of the lean NAFLD patients met the criteria for NASH, which was statistically similar to the prevalence of NASH in the obese NAFLD (38%) patients. The proportion of patients with hepatic fibrosis was significantly lower in the lean NAFLD patients compared to the obese NAFLD patients (50% vs. 84%, *p* \< 0.01).

###### Histological severity of lean NAFLD compared to obese NAFLD

  Study^Ref^             Lean/Obese   NAS (0--8)   Fibrosis                                         NASH NAS \> 4   Advanced Fibrosis \> F2                                                   
  ---------------------- ------------ ------------ ------------------------------------------------ --------------- ------------------------------------------------- ------- ------- ------- -------
  Leung *et al.*[@b4]    72/235       3.3 ± 1.3    3.8 ± 1.2[\*](#table3fn1){ref-type="table-fn"}   1.3 ± 1.5       1.7 ± 1.4[\*](#table3fn1){ref-type="table-fn"}    43.5%   51.9%   26.1%   27.7%
  Alam *et al.*[@b6]     56/164       4.4 ± 1.4    4.1 ± 1.1                                        1.2 ± .8        1.1 ± 0.8                                         53.5%   46.9%   19.6%   18.9%
  Kumar *et al.*[@b5]    18/73        3.3 ± 1.5    4.1 ± 1.4                                        01 (0--04)      02 (0--04)[\*](#table3fn1){ref-type="table-fn"}   28%     38%     5.6%    27%
  Akyuz *et al.*[@b79]   37/446       5 (2--7)     5 (4--6)                                         0 (0--1)        1 (0--2)[\*](#table3fn1){ref-type="table-fn"}     --      --      0       0
  Honda *et al.*[@b8]    134/406      3.5 ± 1.6    4.2 ± 1.5[\*](#table3fn1){ref-type="table-fn"}   1.6 ± 1.1       1.7 ± 1.0                                         --      --              --

Significantly different between lean and obese.

Abbreviations: NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis.

In a recent large series from Hong Kong,[@b4] histological severity and clinical outcome of 72 non-obese (BMI \<25 kg/m^2^) NAFLD patients were compared with 235 obese NAFLD patients. Compared with obese patients, non-obese patients had lower NAFLD activity score (3.3 ± 1.3 vs. 3.8 ± 1.2; *p* = 0.019) and lower fibrosis stage (1.3 ± 1.5 vs. 1.7 ± 1.4; *p* = 0.004). Only elevated serum triglyceride level was independently associated with higher NAFLD activity score (odds ratio: 1.6). Other studies have also reported a lower histological severity in lean NAFLD patients compared to obese NAFLD patients.[@b8],[@b20],[@b79] A study from Bangladesh found no significant difference between histology of lean and obese NAFLD cases.[@b6] Akyuz *et al.*[@b79] reported that higher haemoglobin level predicts the histological severity and suggested that serum haemoglobin level can be used as a biomarker of severity of lean NAFLD. Notably, Yilmaz *et al.*[@b80] previously demonstrated that increased haemoglobin may be a feature of NAFLD patients without MS, for whom it predicts both NASH and fibrosis.

Clinical implications of lean NAFLD {#s12}
===================================

Very little information is available about natural history, prognosis and therapeutic strategies in lean subjects with NAFLD. Moreover, the evolving data have shown mixed results. It has been shown that mortality has a significant association with individuals' BMI. A large pooled analysis found a U-shaped association between BMI and the risk of death in East Asians. Overall, the risk of death among Asians, as compared with Europeans, seems to be more strongly affected by a low BMI than by a high BMI.[@b81] Dela Cruz *et al.*[@b82] followed-up 1,090 NAFLD patients, 125 (11.5%) of who were lean, for 133 months (range 3--332) and found that the cumulative survival was significantly shorter in patients with lean NAFLD compared to those with non-lean NAFLD (log-rank test = 5.6; *p* \< 0.02). This difference in survival remained significant when adjusted in a Cox regression model, with only lean NAFLD (hazard ratio: 11.8; 95% confidence interval: 2.8, 50.1; *p* = 0.001) and age (hazard ratio: 1.05; 95% confidence interval: 1.008, 1.1; *p* = 0.02) remaining significant. The patients with lean NAFLD were more commonly men, of non-Caucasian race, and had a lower prevalence of diabetes, hypertension, hypertriglyceridemia, central obesity and MS, as compared to the non-lean NAFLD patients (*p* \< 0.004 for all). The lean NAFLD group also had significantly lower levels of alanine aminotransferase, lower HOMA-IR, lower degree of steatosis and less advanced fibrosis, but more severe lobular inflammation than the non-lean NAFLD group (*p* \< 0.03 for all).

A recent study from Hong Kong has revealed that non-obese NAFLD (*n* = 72) patients tend to have less severe disease and may have a better prognosis than obese patients (*n* = 235).[@b4] After a median follow-up of 49 months, 6 patients died, all belonging to the obese group. In a series of 1,777 patients with advanced liver disease undergoing liver biopsy, Vos *et al.*[@b20] found that 2.8% (*n* = 50) of subjects neither had obesity nor diabetes, and this was the most common cause of cryptogenic liver disease. Compared with obese patients with NAFLD, lean NAFLD patients also showed lower degrees of hepatic inflammation and fibrosis.[@b20] A study from China described that NAFLD without obesity adds significant risk for DM and MS.[@b9]

There remains a lack of data describing the association between lean NAFLD and cardiovascular disease. Although, Sung *et al.*[@b83] has described that the severity of NAFLD is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects.

Therapeutic implications {#s13}
========================

To date, there is no approved pharmacological therapy for NAFLD. Most clinical attempts have been directed at treating the individual components of MS. Therefore, lifestyle changes targeted at weight loss, dietary modifications and exercise remain the first-line therapy. There is no reliable data to suggest effectiveness of lifestyle modifications in lean patients with NAFLD.

We believe that weight loss can be particularly helpful in a subset of lean NAFLD patients who have visceral obesity. Jin *et al.*[@b84] evaluated the efficacy of dietary modification and exercise on the degree of steatosis, in a study of 1,365 persons with non-obese NAFLD. After lifestyle modification, they found an 86% improvement in the degree of steatosis at the time of follow-up biopsy. On multivariate analysis, weight reduction of ≥5%, higher baseline steatosis, and total cholesterol reduction of ≥10%, were significantly associated with steatosis improvement in non-obese patients with NAFLD. Kim *et al.*,[@b67] in a longitudinal study, found that reduction of body weight was significantly associated with regression of NAFLD in non-obese NAFLD.

Restriction of food and beverages high in fructose or cholesterol may be beneficial in lean NAFLD patients. Dyslipidaemia, which is frequently seen in patients with lean NAFLD, should be treated. An initial attempt should be also made to rule out secondary causes of fatty liver, such as drugs, hypobetalipoproteinaemia, familial hypercholesterolemia, lipodystrophy, celiac disease, etc. Trials exploring the potential effects of anti-oxidants, insulin sensitizers, cytoprotective agents or other modalities on lean NAFLD are eagerly awaited. One of the key areas for future research direction could be the identification of the linkage between significant genes and metabolic pathways involved in the development of lean NAFLD. These biological indicators can be used for novel drug development in the future.

In conclusion, lean NAFLD is now frequently recognised in day-to-day clinical practice; however, the data on epidemiology, risk factors, physiopathology, distinctive histologic changes, natural history and treatment of this entity are still scant. There are limitations in the estimations of precise prevalence of lean NAFLD due to absence of clinical manifestations and poor accuracy of ultrasound for mild steatosis. Researchers have used different BMI cut-offs to define lean NAFLD, which introduce difficulty in interpreting the results of studies and in making meaningful comparisons between studies. From a biological point of view, lean NAFLD behaves much like obese NAFLD; however, the absence of significant adiposity suggests a phenotypic distinctiveness. Compared to obese NAFLD subjects, lean NAFLD subjects appear to have less severe disease. The underlying mechanism is not well known but may hint at genetic and environmental risk factors that may not be present in obese NAFLD. A difficult issue with lean NAFLD patients is how to treat, given the fact that these patients already have normal weight. Therefore, additional works are needed to gain a better understanding of the disease process and implications of NAFLD in lean subjects.
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